Wedbush Has Lowered Expectations for Vigil Neuroscience (NASDAQ:VIGL) Stock Price

Vigil Neuroscience (NASDAQ:VIGL) had its price objective cut by research analysts at Wedbush from $24.00 to $13.00 in a research report issued on Friday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Wedbush also issued estimates for Vigil Neuroscience’s FY2029 earnings at $1.40 EPS.

A number of other analysts have also weighed in on the stock. HC Wainwright decreased their target price on shares of Vigil Neuroscience from $17.00 to $14.00 and set a “buy” rating on the stock in a report on Friday. William Blair assumed coverage on shares of Vigil Neuroscience in a report on Wednesday, December 4th. They set an “outperform” rating on the stock. Guggenheim reaffirmed a “buy” rating on shares of Vigil Neuroscience in a report on Friday, January 24th. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $22.00 target price on shares of Vigil Neuroscience in a report on Tuesday, November 26th. Five analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of “Buy” and a consensus target price of $16.25.

Vigil Neuroscience Stock Down 4.3 %

NASDAQ VIGL opened at $2.02 on Friday. The company’s 50 day moving average is $2.34 and its 200-day moving average is $2.79. Vigil Neuroscience has a 12-month low of $1.49 and a 12-month high of $6.06. The firm has a market cap of $82.58 million, a P/E ratio of -0.98 and a beta of 1.82.

Vigil Neuroscience (NASDAQ:VIGL) last posted its earnings results on Thursday, March 13th. The company reported ($0.57) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.08). Equities analysts expect that Vigil Neuroscience will post -2.07 EPS for the current year.

Hedge Funds Weigh In On Vigil Neuroscience

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Cubist Systematic Strategies LLC grew its stake in Vigil Neuroscience by 53.0% in the 4th quarter. Cubist Systematic Strategies LLC now owns 24,120 shares of the company’s stock worth $41,000 after buying an additional 8,358 shares in the last quarter. Jane Street Group LLC purchased a new stake in shares of Vigil Neuroscience in the 4th quarter valued at $83,000. Barclays PLC boosted its stake in shares of Vigil Neuroscience by 43.6% in the 4th quarter. Barclays PLC now owns 64,049 shares of the company’s stock valued at $109,000 after purchasing an additional 19,436 shares in the last quarter. Northern Trust Corp boosted its stake in shares of Vigil Neuroscience by 29.0% in the 4th quarter. Northern Trust Corp now owns 64,737 shares of the company’s stock valued at $110,000 after purchasing an additional 14,572 shares in the last quarter. Finally, Two Sigma Advisers LP boosted its stake in shares of Vigil Neuroscience by 243.8% in the 4th quarter. Two Sigma Advisers LP now owns 69,100 shares of the company’s stock valued at $117,000 after purchasing an additional 49,000 shares in the last quarter. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.